Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Personalized treatment approaches are needed to address individual patient variability in IPF and PAH.
Enhanced understanding of pathophysiological mechanisms is crucial for novel therapeutic target development.

Steven Nathan, MD, discusses additional noteworthy data from CHEST 2024 on emerging therapies for IPF and PAH and highlights his excitement for ongoing research focused on improving early detection, personalized treatments, and improving long-term patient outcomes.

EP: 1.CHEST 2024: Updates in IPF and PAH Care

EP: 2.Key Predictors of Survival in IPF: Findings From the IPF-PRO Registry

EP: 3.Implications of IPF Survival Data for Clinical Practice and Early Intervention

EP: 4.Evaluating Cough Relief With Oral Nalbuphine in Patients With IPF

EP: 5.Insights on Managing Cough Symptoms in Patients With IPF

EP: 6.Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH

Now Viewing

EP: 7.Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF

Please discuss any other data in IPF or PAH released at CHEST 2024 that you find noteworthy to share with colleagues.
Outside of CHEST 2024, what ongoing research efforts are you most excited about in the treatment and management of IPF and PAH, and what are some key areas where you think further research is needed to continue improving patient outcomes?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF

Key Takeaways